A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting ß2 Agonist in Patients with Uncontrolled Asthma (SIRO